Daniel Lang

Chief Financial Officer

Dr. Lang joined CASI in July 2024 as CFO and SVP of CASI Pharmaceuticals, Inc. 

Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform.

He completed his cardiology fellowship at UCSF and Gladstone Cardiovascular Research Institute. He obtained his MD degree from Cornell University Medical College and BA in Chemistry from Cornell University.